Stemcell United

Stemcell United Equity Ratio

The Equity Ratio of Stemcell United (SCU.AX) as of Nov 16, 2026 is 39.92 %. In the previous year, Equity Ratio was 60.08 % — a change of -33.54% (lower).

Equity Ratio

39.92 %

YoY

-33.54%

Last updated:

Equity Ratio of Stemcell United is 2022 39.92 % . Equity Ratio of Stemcell United was 2021 60.08 % . It decreases by -33.54% lower compared to the previous year.

The Stemcell United Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2015
4.18 AUD
Jan 1, 2016
85.12 AUD
Jan 1, 2017
80.68 AUD
Jan 1, 2018
75.91 AUD
Jan 1, 2019
69.45 AUD
Jan 1, 2020
45.65 AUD
Jan 1, 2021
60.08 AUD
Jan 1, 2022
39.92 AUD
The Stemcell United Equity Ratio history
YEAREquity RatioYoY
39.92 %-33.54%
60.08 %+31.61%
45.65 %-34.27%
69.45 %-8.51%
75.91 %-5.91%
80.68 %-5.21%
85.12 %+1,933.90%
4.18 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Stemcell United Stock analysis

What does Stemcell United do? Stemcell United Ltd is an internationally operating company that is active in the field of stem cell research and therapy. It was founded in 2005 by British entrepreneur and scientist Dr. Samantha Phillips, who previously worked for the renowned Roslin Institute for Animal Genetics. The business model of Stemcell United is based on the development and distribution of innovative therapies that are based on the use of stem cells as a foundation. The company primarily relies on close collaboration with leading research institutions and clinics worldwide to stay up to date with the latest research and develop products and services that are based on current knowledge and meet the highest quality standards. The various divisions of Stemcell United include the development and production of stem cell-based therapies for diseases such as cancer, heart attack, dementia, and stroke. Additionally, the company also offers support and consultation in the field of clinical trials as well as training for doctors and researchers to improve and optimize the use of stem cell therapies. Another important area of Stemcell United's business activities is the production and marketing of stem cells for research purposes. Both embryonic and adult stem cells are produced and provided to advance research in this field and gain new insights. The products offered by Stemcell United mainly include stem cell preparations for wound healing and tissue regeneration, as well as specialized cell cultures for research in the field of stem cell therapy. These products are sold to clinics, research institutions, and end consumers and are available in many countries worldwide. In recent years, Stemcell United has become one of the leading companies in the field of stem cell research and therapy and enjoys a high reputation in the industry. The company primarily relies on close collaboration with other top companies in the industry and a strong connection to research and development in this field. Overall, Stemcell United is an innovative and dynamic company that sets standards in the field of stem cell research and therapy worldwide and constantly seeks new ways to utilize the possibilities of stem cell therapy for the health and well-being of humans and animals. Stemcell United is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Stemcell United stock

Equity Ratio of Stemcell United is 39.92 % in 2022.

Equity Ratio of Stemcell United changed from 60.08 % to 39.92 %, representing a -33.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Stemcell United since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Stemcell United with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Stemcell United

All Key Metrics — Stemcell United